# Severe Asthma Biologic Selection

Select an asthma biologic only after confirming severe asthma, correcting modifiable drivers, documenting exacerbation burden, and matching allergic or type 2 biomarkers, oral corticosteroid dependence, and relevant comorbidities to a single targeted agent.

**Clinical question:** How should clinicians select a biologic for adults with severe asthma after optimized inhaled therapy?

Updated: 2026-09-15T18:09:37.792538+00:00

## What matters in practice
- Do not label asthma as severe or initiate a biologic until the diagnosis is confirmed and adherence, inhaler technique, and comorbid contributors have been addressed. [6][9][16]
- For persistent exacerbations despite optimized high-dose inhaled corticosteroid plus controller therapy, blood eosinophils, FeNO, allergen sensitization, total IgE, body weight, and maintenance oral corticosteroid exposure guide biologic eligibility. [5][8][10][11]
- Use anti-IgE treatment for allergic asthma with demonstrated aeroallergen sensitization and total IgE plus body weight within the dosing range; use anti-IL-5/IL-5R therapy principally for eosinophilic disease. [8][21]
- Eosinophils of at least 300 cells/μL support anti-IL-5/IL-5R eligibility in GINA-based criteria, whereas ERS/ATS uses at least 150 cells/μL; select the threshold required by the applicable product, payer, and local pathway. [5][8]
- Dupilumab is an option for severe eosinophilic/type 2 asthma when eosinophils are at least 150 cells/μL or FeNO is at least 25 ppb, and for oral corticosteroid-dependent asthma regardless of eosinophil count in ERS/ATS guidance. [5][8]
- When more than one biologic is plausible, prioritize the dominant treatable trait and comorbid type 2 disease; comparative head-to-head efficacy evidence remains limited. [7][14]

## Confirm that uncontrolled disease is truly severe asthma

Biologic selection begins after excluding remediable causes of apparent treatment failure.

Use the ERS/ATS severe-asthma construct: asthma requiring high-dose inhaled corticosteroid (ICS) plus a second controller and/or systemic corticosteroids to prevent loss of control, or asthma remaining uncontrolled despite that treatment. Confirm the asthma diagnosis before applying this label, and reassess relevant comorbidities before escalating to a biologic. [1][16]

Document current controller dispensing and observed inhaler technique before referral or authorization. In a U.S. claims analysis of patients escalated to biologics, 63% had suboptimal maintenance-medication adherence, defined as proportion of days covered below 80%; a biologic should not substitute for correcting avoidable underexposure to ICS-based therapy. [6]

Use a structured difficult-asthma assessment when control remains poor. Specialist review that includes diagnostic reassessment, treatment optimization, adherence and inhaler-technique intervention, and self-management education has been associated with improved control, lung function, exacerbation outcomes, and reduced oral corticosteroid burden. [9]
- Record exacerbations during the preceding 12 months, including systemic corticosteroid bursts, emergency care, hospitalization, ICU admission, and mechanical ventilation; two or more systemic corticosteroid courses in the prior year is a frequent-exacerbation criterion used in severe-asthma definitions. [18]
- Document baseline symptom burden with a validated instrument when available: ACT below 20 or ACQ above 1.5 identifies uncontrolled symptoms in a severe-asthma registry protocol. [18]
- Obtain spirometry with bronchodilator testing when feasible. A negative bronchodilator response does not exclude asthma in a patient already receiving inhaled therapy; visit-to-visit FEV1 variability, home peak-flow variability greater than 10%, or bronchial challenge testing may provide objective support. [15]

*Pre-biologic confirmation steps that change whether escalation is appropriate. [6][9][16][18]*

| Clinical question | Actionable assessment | What the result changes |
| --- | --- | --- |
| Is asthma objectively supported? | Perform spirometry with bronchodilator testing when feasible; if nondiagnostic, assess serial FEV1 or home peak expiratory flow variability and consider bronchial challenge testing. [15] | Avoid assigning refractory disease without objective diagnostic review; pursue alternative or coexisting explanations for airflow symptoms when objective evidence is absent. [15][16] |
| Is disease uncontrolled at high treatment intensity? | Verify high-dose ICS plus a second controller and document exacerbations, ACT, ACQ, lung function, and systemic corticosteroid exposure. [1][16][18] | Establishes whether the patient meets a severe-asthma phenotype rather than undertreated asthma. [1][16] |
| Is poor control modifiable? | Review dispensing history, adherence, inhaler technique, and comorbid contributors. Proportion of days covered below 80% indicates suboptimal maintenance adherence. [6][9] | Correct modifiable drivers before attributing persistent symptoms or exacerbations to biologic-refractory inflammation. [6][9] |

## Obtain biomarkers during stable disease and interpret them as treatment-selection signals

Use several biomarkers rather than a single laboratory value when phenotypes overlap.

For a patient with confirmed severe asthma and persistent exacerbations despite optimized inhaled therapy, obtain blood eosinophils, FeNO, total serum IgE, and aeroallergen sensitization by skin-prick testing or allergen-specific IgE. Blood eosinophils, FeNO, and total IgE are the principal biomarkers used in clinical phenotyping for type 2-high and type 2-low asthma. [8][11]

Interpret blood eosinophils and FeNO in the context of ongoing corticosteroid treatment. Blood eosinophils of at least 150 cells/μL and FeNO of at least 20 ppb despite treatment indicate residual type 2 inflammation; higher eosinophils and FeNO predict greater expected response to dupilumab. [5][10]

If eosinophilic and allergic signals coexist, do not infer that one class is universally superior. Patients may meet eligibility criteria for both anti-IgE and anti-IL-5/IL-5R treatment, while direct comparative evidence is limited and an indirect comparison found no difference in comparative effectiveness or tolerability between anti-IL-5 and anti-IgE therapy in overlapping eligible populations. [14]
- Anti-IgE eligibility requires sensitization to common aeroallergens plus total serum IgE and body weight within the agent's dosing range. [8]
- GINA-based anti-IL-5/IL-5R eligibility commonly uses blood eosinophils of at least 300 cells/μL; ERS/ATS guidance uses at least 150 cells/μL. [5][8]
- GINA-based dupilumab eligibility for severe eosinophilic asthma includes blood eosinophils of at least 150 cells/μL or FeNO of at least 25 ppb with prior-year exacerbations. [5][8]

*Biomarker patterns used to direct initial biologic class selection in severe asthma. [5][8][10][21]*

| Treatable pattern | Required or supportive findings | Initial biologic-class direction |
| --- | --- | --- |
| Allergic asthma | Aeroallergen sensitization by skin testing or specific IgE; total IgE and body weight within dosing range. [8] | Anti-IgE therapy, represented by omalizumab. [8][21] |
| Eosinophilic asthma | Blood eosinophils at least 300 cells/μL in GINA-based criteria or at least 150 cells/μL in ERS/ATS guidance. [5][8] | Anti-IL-5 or anti-IL-5R therapy, represented by mepolizumab, reslizumab, or benralizumab. [5][21] |
| Type 2 asthma with elevated FeNO | FeNO at least 25 ppb in GINA-based dupilumab criteria; FeNO at least 20 ppb despite treatment signals residual type 2 inflammation. [5][10] | Consider anti-IL-4Rα therapy with dupilumab, particularly when eosinophils and FeNO are both elevated. [5] |
| Oral corticosteroid-dependent asthma | Maintenance oral corticosteroid requirement after optimized inhaled treatment and severe-asthma assessment. [5][6] | Dupilumab is supported in ERS/ATS guidance regardless of eosinophil count; anti-IL-5/IL-5R therapy is also used for eosinophilic disease. [5][21] |
| No clear allergic or eosinophilic eligibility pattern | Low or nonqualifying biomarkers after confirming adherence, diagnosis, and comorbidity management. [6][11] | Do not force a phenotype-specific biologic choice; reassess the difficult-asthma evaluation and consider an agent with broader severe-asthma positioning within specialist care. [7][13][21] |

## Match one biologic to the dominant clinical trait

Use eligibility markers to narrow choices, then use corticosteroid exposure and comorbid disease to select among overlapping options.

Choose anti-IgE therapy when allergic sensitization is unequivocal and the patient's total IgE and body weight fit the dosing framework. Omalizumab is the established anti-IgE option; its selection depends on allergic phenotype rather than blood eosinophil count alone. [8][21]

Choose an IL-5-pathway strategy when recurrent exacerbations occur in eosinophilic asthma. Mepolizumab and benralizumab are identified for severe eosinophilic asthma, and reslizumab is another anti-IL-5 option. A blood eosinophil count meeting the applicable threshold supports this branch, but the decision should remain anchored to prior exacerbations despite optimized standard therapy. [5][8][21]

Choose dupilumab when type 2 biology is signaled by eosinophils of at least 150 cells/μL or FeNO of at least 25 ppb in a patient with prior-year exacerbations, or when maintenance oral corticosteroid dependence is the dominant problem. Elevated eosinophils and FeNO are associated with greater expected response, whereas ERS/ATS guidance permits use in corticosteroid-dependent severe asthma regardless of eosinophil count. [5][8]

For patients eligible for several agents, select the therapy most likely to address the dominant asthma trait and relevant type 2 comorbidities, while incorporating dosing burden, prior response, and patient preference. There are no robust head-to-head comparative trials sufficient to establish a universal rank order among biologics. [7][14]
- Do not combine two asthma biologics routinely. Expert drug-plan guidance states that tezepelumab should not be used in combination with another asthma biologic, and published combination experience is limited to case series and reports. [21][24]
- A switch to another biologic monotherapy is the preferred strategy when the initial biologic fails to achieve adequate control; case-series experience with combination treatment generally followed an unsuccessful monotherapy switch attempt. [24]
- Avoid concurrent live vaccines with dupilumab or tezepelumab based on reported interaction guidance. [20]

### When a broader mechanism is considered

Tezepelumab has a broader severe-asthma indication profile than phenotype-restricted anti-IgE and anti-IL-5/IL-5R therapies in expert summaries, but selection should still follow confirmation of severe asthma, optimization of standard therapy, and assessment by a clinician experienced in asthma biologics. [13][21]

*Practical class selection when severe asthma remains uncontrolled after optimization. [5][8][21]*

| Dominant decision driver | Preferred class or agent direction | Selection caveat |
| --- | --- | --- |
| Sensitized allergic asthma with IgE and weight in range | Anti-IgE: omalizumab. [8][21] | Confirm sensitization and dosing-range eligibility; eosinophilia alone does not establish anti-IgE eligibility. [8] |
| Eosinophilic exacerbation-prone asthma | Anti-IL-5/IL-5R: mepolizumab, benralizumab, or reslizumab. [5][21] | Use the biomarker cutoff specified by the governing pathway: at least 300 cells/μL in GINA-based criteria versus at least 150 cells/μL in ERS/ATS guidance. [5][8] |
| Elevated FeNO and/or eosinophilic type 2 asthma | Anti-IL-4Rα: dupilumab. [5][8][21] | GINA-based eligibility uses eosinophils at least 150 cells/μL or FeNO at least 25 ppb; higher values predict better response. [5][8] |
| Maintenance oral corticosteroid dependence | Dupilumab is an ERS/ATS-supported option regardless of eosinophil count; assess eosinophilic eligibility for IL-5-pathway therapy concurrently. [5][21] | Plan steroid reduction only after clinical response is established and continue to monitor for loss of control. [22] |
| Overlapping allergic and eosinophilic eligibility | Choose one agent based on dominant trait and comorbid disease burden. [7][14] | No definitive comparative trial evidence establishes a universally preferred first agent. [7][14] |

## Measure clinical response, reduce corticosteroid exposure, and switch rather than combine

Continue high-value asthma assessments after biologic initiation; biomarker eligibility is not itself a response endpoint.

At each follow-up, quantify exacerbations requiring systemic corticosteroids, emergency or hospital care, maintenance oral corticosteroid exposure, symptom control using ACT or ACQ, lung function, and treatment adherence. These outcomes align with the goals of biologic treatment: fewer exacerbations and hospitalizations, improved disease control, and lower corticosteroid burden. [12][17][23]

If maintenance oral corticosteroids are being used, make reduction of systemic corticosteroid burden an explicit outcome. Biologics are commonly initiated in severe uncontrolled asthma to replace or reduce oral corticosteroids, but withdrawal should be guided by sustained asthma control and monitored for deterioration. [22]

If the selected biologic does not produce meaningful improvement in the patient's dominant baseline problem, repeat the systematic assessment before changing class: verify asthma diagnosis, adherence, inhaler technique, exacerbation attribution, and current biomarker pattern. If persistent severe asthma is confirmed, switch to a different biologic monotherapy rather than empirically adding a second asthma biologic. [9][21][24]
- Record injection-site reactions, nasopharyngitis, headache, and hypersensitivity events, which are among commonly reported adverse reactions across asthma biologics. [22]
- Review planned immunizations before starting dupilumab or tezepelumab because concurrent live vaccines should be avoided. [20]
- Do not use response to a biologic as the sole confirmation of an asthma diagnosis; retain objective assessment and reassess alternative causes when control remains poor. [9][15][16]

*Post-initiation assessment separates treatment response from persistent difficult asthma. [9][17][22][24]*

| Finding at follow-up | Interpretation | Next action |
| --- | --- | --- |
| Fewer exacerbations and lower systemic corticosteroid exposure | Clinical response consistent with the intended risk-reduction goal of biologic treatment. [17][22][23] | Continue the biologic and maintain reassessment of control, lung function, adverse effects, adherence, and corticosteroid burden. [22][23] |
| Persistent exacerbations despite biologic treatment | May represent inadequate biologic response, persistent exposure or adherence problems, diagnostic error, or unaddressed comorbidity. [9][24] | Repeat systematic difficult-asthma assessment and reconsider phenotype-directed monotherapy. [9][24] |
| Inadequate control after confirmed appropriate monotherapy | A biologic switch may be appropriate after reassessing the dominant asthma and comorbidity traits. [24] | Switch to an alternative biologic monotherapy; do not routinely combine asthma biologics. [21][24] |
| New systemic symptoms or suspected hypersensitivity | Potential biologic adverse reaction requires clinical attribution and severity assessment. [22] | Assess promptly and determine whether treatment interruption or discontinuation is necessary based on clinical severity. [22] |

## Common questions

### Should an elevated FeNO alone direct biologic selection?

FeNO of at least 25 ppb meets a GINA-based dupilumab eligibility pathway when prior-year exacerbations persist despite severe-asthma therapy; FeNO of at least 20 ppb despite treatment supports residual type 2 inflammation. Interpret it with blood eosinophils, exacerbation history, adherence, and allergic testing rather than as a standalone diagnosis. [5][8][10][11]

### Can two asthma biologics be prescribed together for persistent severe asthma?

Routine dual-biologic treatment should be avoided. Guidance for tezepelumab advises against combining it with another asthma biologic, and the published experience with combinations is limited largely to case series. Reassess phenotype and switch monotherapy when response is inadequate. [21][24]

## References
1. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era — thorax.bmj.com — https://thorax.bmj.com/content/76/3/220
2. 2020 Asthma Guideline Update From the National ... - JAMA Network — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/2773482
3. Biologic Therapies for Severe Asthma — www.nejm.org — https://www.nejm.org/doi/pdf/10.1056/NEJMra2032506
4. Guideline-driven and dependable management of... : Annals of Medicine & Surgery — journals.lww.com — https://journals.lww.com/annals-of-medicine-and-surgery/_layouts/15/oaks.journals/downloadpdf.aspx?an=01845215-202508000-00061
5. Characteristics, phenotypes, mechanisms and... : Chinese Medical Journal — journals.lww.com — https://journals.lww.com/cmj/_layouts/15/oaks.journals/downloadpdf.aspx?an=00029330-202205200-00003
6. Assessment of Real-World Escalation to Biologics in US Patients With Asthma - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2213219822007164
7. Biologic Management in Severe Asthma for Adults : Chest — journals.lww.com — https://journals.lww.com/00002953-202602000-00010
8. Eligibility of C-BIOPRED severe asthma cohort for... : Chinese Medical Journal — journals.lww.com — https://journals.lww.com/cmj/fulltext/2023/01200/eligibility_of_c_biopred_severe_asthma_cohort_for.15.aspx
9. Systematic Assessment for Difficult and Severe Asthma Improves Outcomes and Halves Oral Corticosteroid Burden Independent of Monoclonal Biologic Use - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2213219820300374
10. Guidance for type 2 inflammatory biomarkers - ScienceDirect.com — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2212534525000048
11. Phenotyping of Severe Asthma in the Era of Broad-Acting Anti ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2213219824000758
12. [PDF] PROTOCOL CHECKLIST - HMA-EMA Catalogues — catalogues.ema.europa.eu — https://catalogues.ema.europa.eu/system/files/2024-10/REG_Time%20to%20Biologics%20Protocol.pdf
13. New guidelines to treat severe asthma recommend ‘evaluating first, treating second’ - CHEST Physician — chestdailynews.chestnet.org — https://chestdailynews.chestnet.org/new-guidelines-to-treat-severe-asthma-recommend-evaluating-first-treating-second
14. [PDF] The comparative effectiveness across severe asthma biologic ... — catalogues.ema.europa.eu — https://catalogues.ema.europa.eu/sites/default/files/document_files/ISAR_OPCG1903_Effectiveness%20across%20Bx%20classes_Protocol%2013%20Aug%202020.pdf
15. GINA vs ATS/ERS Bronchodilator Responsiveness Thresholds vs Alternative Routes of Diagnosis in Severe or Difficult to Control Asthma | American Journal of Respiratory and Critical Care Medicine — www.atsjournals.org — https://www.atsjournals.org/doi/10.1164/ajrccm.2025.211.Abstracts.A3072
16. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24337046
17. Efficacy of azithromycin in severe asthma from the AMAZES randomised trial - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6926362
18. [PDF] 1 | Page RSAR Registry Protocol D-code: D3250R00040 Tracking ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/66/NCT03608566/Prot_SAP_000.pdf
19. [PDF] Utilizing CT Based Imaging Parameters of Body Composition to ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/60/NCT06922760/Prot_SAP_000.pdf
20. A retrospective study on potential drug‒drug interactions in patients with severe asthma receiving biological therapy: a single-center experience — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11737206
21. Table 4, Summary of Drug Plan Input and Clinical Expert Response - Tezepelumab (Tezspire) - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK601779/table/tr8269861151140731_ch01_t04?report=objectonly
22. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11055782
23. Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE) — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13160935
24. Combination of Biological Therapy in Severe Asthma: Where We Are? — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10672189

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.